Loading clinical trials...
Loading clinical trials...
Postoperative Glucose Control with a Basal Bolus Versus Sliding Scale Insulin Regimen and Its Effect on the Incidence of Surgical Site Infections in People with Type 2 Diabetes Mellitus.
A multicentre, matched-pair, cluster randomised controlled superiority trial to investigate the effect of a proactive basal bolus insulin regimen compared to the reactive sliding scale insulin regimen, targeting a glucose level of 3.9-10.0 mmol/L, to reduce the number of surgical site infections within the first 30 days postoperatively in adult patients with diabetes mellitus type 2.
People with type 2 diabetes mellitus (PWT2D) are at increased risk of postoperative complications, especially surgical site infections (SSI). The aim of this study to reduce SSI in PWT2D by implementing a proactive basal-bolus insulin regimen, compared to the reactive sliding scale regimen. Adult patients with type 2 diabetes will be included in this multi-centre study. Participants will receive a blind CGM, i.e. glucose data are masked for the participants and study team, from admission to the ward until discharge from the hospital. In addition, all participants are asked to complete several questionnaires 30 days after surgery. Both regimens are currently used in clinical practice. Therefore, there is no additional trial-related burden depending on the intervention group allocation. Participants will be monitored intensively and insulin dosage will be adjusted adequately to the measured glucose values by the treatment team. The sample size is based on the SSI incidence rates. Wards are matched into pairs with comparable baseline incidence rates and in each pair, one ward will be randomly assigned to the intervention group; the other serves as the control. 18 wards from 8 participating centres are planned to be recruited, this translates to 9x2x56=1008 evaluable participants. Keywords: Diabetes mellitus, basal bolus, sliding scale, insulin regimen, surgical site infections
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Amsterdam UMC
Amsterdam, Netherlands
Start Date
January 3, 2025
Primary Completion Date
February 1, 2027
Completion Date
September 1, 2027
Last Updated
January 30, 2025
1,008
ESTIMATED participants
Basal bolus insulin regimen
OTHER
Lead Sponsor
Abraham Hulst, MD, PhD
Collaborators
NCT06959901
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06861062